Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells.
about
The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistanceHuman cancer cells retain modest levels of enzymatically active matriptase only in extracellular milieu following induction of zymogen activationMatriptase activation, an early cellular response to acidosis.TMPRSS2, a serine protease expressed in the prostate on the apical surface of luminal epithelial cells and released into semen in prostasomes, is misregulated in prostate cancer cellsDiversity of matriptase expression level and function in breast cancer.Endogenous expression of matriptase in neural progenitor cells promotes cell migration and neuron differentiation.The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.Increased matriptase zymogen activation in inflammatory skin disorders.Matriptase: potent proteolysis on the cell surface.Detection of active matriptase using a biotinylated chloromethyl ketone peptideMatriptase is inhibited by extravascular antithrombin in epithelial cells but not in most carcinoma cellsCorin in clinical laboratory diagnosticsAndrogen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase.Mechanisms for the control of matriptase activity in the absence of sufficient HAI-1Natural Endogenous Human Matriptase and Prostasin Undergo Zymogen Activation via Independent Mechanisms in an Uncoupled Manner.Purification from human milk of matriptase complexes with secreted serpins: mechanism for inhibition of matriptase other than HAI-1.Matriptase activation and shedding through PDGF-D-mediated extracellular acidosis.Polarized epithelial cells secrete matriptase as a consequence of zymogen activation and HAI-1-mediated inhibition.Strong expression association between matriptase and its substrate prostasin in breast cancer.Autoactivation of matriptase in vitro: requirement for biomembrane and LDL receptor domain.Matriptase shedding is closely coupled with matriptase zymogen activation and requires de novo proteolytic cleavage likely involving its own activity.The Kunitz Domain I of Hepatocyte Growth Factor Activator Inhibitor-2 Inhibits Matriptase Activity and Invasive Ability of Human Prostate Cancer Cells.Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis.Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.Reduced urinary corin levels in patients with chronic kidney disease.
P2860
Q28076745-C8EA50A5-D42A-4D89-8FC2-A6DD509778B0Q28541376-6A5AB8A0-9F97-4774-B5C4-B30113DF8A48Q33661373-DCD37589-7A6A-4A1D-B9FC-79CDD6DE2846Q33882562-F122EF85-D925-4F81-A183-DFF80BF0E4B0Q34238503-B1DF9BED-2310-443C-B2D8-0B75F26B9612Q34568589-7EB25AFF-794C-43FB-8014-3A640C68A700Q34699785-77FE6FBE-31FE-4BCA-9179-340471EC32BFQ34717980-37BC1814-30F7-4488-A50D-CD383A7E9BD0Q34809525-A0F3C6BC-0D5E-431B-B650-AF5F2B0E95B3Q35035059-BF82C5D7-24C2-4E29-ADB3-D37FD4465B7CQ35543249-289E8661-E514-44F7-B336-E8D920C5307DQ35634038-424D86E3-1842-4461-89D4-B50F558F7637Q35740095-EA208401-41AA-42D9-A65C-3650C509A42DQ35895533-49CD1A9E-BE5C-4777-827A-4AAB3D32FD8FQ36217915-05F65264-569A-40D2-A69F-BB7CBD44ED1BQ36842289-A194038C-EE06-4956-90A0-16A6BBEFB476Q37218017-00891585-7A2E-46F7-82E6-506A68D85DB3Q37298015-B63E82F9-BE98-42E3-B0E2-4FFD2553A684Q39523621-E1A1F8CA-40F8-4AB1-BD69-5F7A62A76E13Q40161979-70637257-4A29-44F7-8BB4-3E96C51F40B7Q41492870-9118ADD2-5552-4C4F-90C0-057504AACA2DQ47171613-7CE8F197-81A0-4EA8-A96A-CCEC8DD6DFC3Q51075784-D3B99EDE-1AB6-4C1D-B353-B3EFBE4ACFAFQ52661781-B7654F24-9D1C-4C8D-B4B1-AB96D2AF8522Q54275293-599C9C2E-8D81-4E38-96B4-498D7DEC2946
P2860
Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Matriptase activation and shed ...... ut not in breast cancer cells.
@en
Matriptase activation and shed ...... ut not in breast cancer cells.
@nl
type
label
Matriptase activation and shed ...... ut not in breast cancer cells.
@en
Matriptase activation and shed ...... ut not in breast cancer cells.
@nl
prefLabel
Matriptase activation and shed ...... ut not in breast cancer cells.
@en
Matriptase activation and shed ...... ut not in breast cancer cells.
@nl
P2093
P2860
P1476
Matriptase activation and shed ...... but not in breast cancer cells
@en
P2093
Chen-Yong Lin
I-Chu Tseng
Ken-ichi Kiyomiya
Michael D Johnson
Robert B Dickson
Robert J Barndt
P2860
P356
10.1152/AJPCELL.00351.2005
P577
2006-02-08T00:00:00Z